MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2022.12.017

Медицинская библиотека · Transplantation and cellular therapy · 2022

Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

Shaw Bronwen E, Jimenez-Jimenez Antonio Martin, Burns Linda J, Logan Brent R, Khimani Farhad, Shaffer Brian C, Shah Nirav N, Mussetter Alisha, Tang Xiao-Ying, McCarty John M, Alavi Asif, Farhadfar Nosha, Jamieson Katarzyna, Hardy Nancy M, Choe Hannah, Ambinder Richard F, Anasetti Claudio, Perales Miguel-Angel, Spellman Stephen R, Howard Alan, Komanduri Krishna V, Luznik Leo, Norkin Maxim, Pidala Joseph A, Ratanatharathorn Voravit, Confer Dennis L, Devine Steven M, Horowitz Mary M, Bolaños-Meade Javier

Многоцентровое исследованиеСтатьяПоддержка службы здравоохранения СШАПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПоддержка правительства СШАПеревод в очереди

Аннотация

The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year outcomes of the first multicenter prospective clinical trial using PTCy in the setting of mismatched unrelated donor (MMUD) bone marrow HCT. The study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity conditioning (RIC; n = 40), with the primary endpoint of 1-year overall survival (OS). The median follow-up for this study was 34 months (range, 12 to 46 months) in the RIC group and 36 months (range, 18 to 49 months) in the MAC group. Three-year OS and nonrelapse mortality were 70% and 15%, respectively, in the RIC group and 62% and 10% in the MAC group. No GVHD was reported after 1 year. The incidence of relapse was 29% in the RIC group and 51% in the MAC group. OS did not differ based on HLA match grade (63% in the 7/8 strata and 71% in the 4 to 6/8 strata). These encouraging outcomes, which were sustained for 3 years post-HCT, support the continued exploration of MMUD HCT using a PTCy platform. Important future areas to address include relapse reduction and furthering our understanding of optimal donor selection based on HLA and non-HLA factors.

Для цитирования: Shaw Bronwen E, Jimenez-Jimenez Antonio Martin, Burns Linda J, Logan Brent R, Khimani Farhad, Shaffer Brian C, Shah Nirav N, Mussetter Alisha, Tang Xiao-Ying, McCarty John M, Alavi Asif, Farhadfar Nosha, Jamieson Katarzyna, Hardy Nancy M, Choe Hannah, Ambinder Richard F, Anasetti Claudio, Perales Miguel-Angel, Spellman Stephen R, Howard Alan, Komanduri Krishna V, Luznik Leo, Norkin Maxim, Pidala Joseph A, Ratanatharathorn Voravit, Confer Dennis L, Devine Steven M, Horowitz Mary M, Bolaños-Meade Javier. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.. Transplantation and cellular therapy. 2022. DOI: 10.1016/j.jtct.2022.12.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.